Trials / Terminated
TerminatedNCT04208698
A Scintigraphy Study in Adults With Diabetic Gastroparesis
A Randomized, Double-Blind Placebo-Controlled Scintigraphy Study to Investigate the Effect of CIN-102 on Gastric Emptying and Antral Contractility in Adults With Diabetic Gastroparesis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- CinDome Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
Detailed description
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1 or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two cohorts with approximately 15 subjects in each cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CIN-102 Dose 1 | Deuterated domperidone (deudomperidone) |
| DRUG | CIN-102 Dose 2 | Deuterated domperidone (deudomperidone) |
| DRUG | Placebo for CIN-102 | Placebo |
Timeline
- Start date
- 2020-02-17
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
- First posted
- 2019-12-23
- Last updated
- 2021-08-10
- Results posted
- 2021-08-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04208698. Inclusion in this directory is not an endorsement.